Vidcast:  https://youtu.be/oh_JQiPfRDM

 

I told you about an RSV vaccine for prospective moms that protects their newborn infants.  Now AstraZeneca and Sanofi have partnered to create, test, and market a drug that squelches newborn RSV infections after they occur.  The new pharmaceutical, the monoclonal antibody nirsevimab, blocks RSV’s fusion protein so that the virus cannot enter human cells and replicate.  Branded as Beyfortus, the antibody has a long life that permits it last the entire RSV season and protect for the first 6 months of life.  The drug has received marketing authorization from the European Commission and will likely receive the same from the FDA and CDC.

 

https://medcitynews.com/2022/11/astrazeneca-sanofi-win-european-nod-for-rsv-preventing-drug-for-infants/

 

#rsv #monoclonal #antibody #nirsevimab #beyfortus #europeanunion